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ABSTRACT
Vemurafenib has been approved in the United States for the treatment of
relapsed or refractory BRAF mutation positive malignant melanoma and is
being investigated in various other malignancies. The RAS/RAF/MEK/ERK
(MAPK) pathway is critical to cell proliferation in many human cancers. The
mTOR inhibitors are well known to exert profound anticancer effects across
malignancies through inhibition of the PTEN/PI3K/AKT/mTOR (mTOR)
pathway. We hypothesize that the toxicity profile of the combination of
vemurafenib and everolimus will be well tolerated. The primary objective
is to find the maximum tolerated dose (MTD) and the toxicity of the
combination of vemurafenib and everolimus following a standard 3 + 3
design. The most common diagnosis was melanoma in 5 out of 10 patients
6

(50%). Male patients in 7 out of 10 patients (70%). The average age was
63.5 years. Two out of 10 patients (20%) had partial responses and an
additional 2 out of 10 patients (20%) had stable disease.
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SPECIFIC AIMS
(I) Background and significance: Vemurafenib has been approved in
United States for treating relapsed/refractory BRAF mutation positive
malignant melanoma and is being investigated in various other
malignancies. The RAS-RAF-MEK-ERK (MAPK) pathway has been deemed
critical to cell proliferation in several human cancer models. The
frequency of such BRAF activating mutation and the resultant oncogene
addiction makes mutated BRAF an extremely attractive target. Combining
multiple agents with different mechanisms of action is now a paradigm in
oncology phase I clinical trials. The BRAF inhibitor vemurafenib has been
selected as the backbone of this trial. The mTOR inhibitors, such as
everolimus and temsirolimus, are well known to exert profound
anticancer effects across malignancies via inhibiting the PTEN-PI3K-AKTmTOR (mTOR) molecular axis. It is possible that combining an inhibitor of
BRAF plus an inhibitor of mTOR will be synergistic and might assist
overcoming resistance to single agents targeted individually to the mTOR
or MAPK signaling pathways. To our knowledge, there are no clinical
trials currently evaluating such combination. Therefore, we have designed
13

a phase I trial evaluating such therapeutic combination in patients with
advanced cancer.
(II) Hypothesis: We hypothesize that the toxicity of combined vemurafenib
plus everolimus will be well tolerated.
(III) Specific aims:
Primary Objective: To determine the maximum-tolerated dose (MTD) of
combined of vemurafenib and everolimus.
Secondary Objective: To describe preliminary antitumor activity (tumor
response) of the combination of vemurafenib and everolimus. In the MTD
expansion phase, correlate responses to treatment with mutations in the
PTEN-PI3K-AKT-mTOR (mTOR) and/or RAS-RAF-MEK-ERK (MAPK)
signaling axis and/or other signaling aberrations.
(IV) Brief methodology: The definition of dose-limiting toxicity (DLT) is
any grade 3/4 that is non-hematologic; or any grade 4 hematologic side
effect lasting two weeks or longer. Three patients will be treated per dose
level with standard 3 + 3 design; three individuals will be dosed at dose
level I and assessed for toxicity. If 0/3 individuals undergo DLT, the next
3-patient cohort will be dosed at the next higher level. If 1 of 3
14

individuals (1/3) dosed at a particular level undergoes DLT, then 3 more
individuals will be dosed at the same dose. In summary, MTD is the
highest level assessed with a DLT incidence lower than 33%. Patients will
continue on the study until their disease has progressed, they elect to
come off the study, they experience unacceptable toxicities.
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INTRODUCTION:

The PTEN-PI3K-AKT-mTOR (mTOR) and RAS-RAF-MEK-ERK (MAPK)
signaling axis (Figure 1) have been deemed key contributors to tumor growth and
are among the most frequently activated in cancer. The RAS-RAF-MEK-ERK axis
is one of the critical paths in neoplasia which may be constitutively activated via
modification of particular proteins, as BRAF, that phosphorylates MEK on
particular regulator residues as serine. Reports of mutated BRAF mutations have
been mentioned at high frequency in multiple neoplastic disorders (e.g. 60% of
melanoma [1], 30% to 50% in papillary thyroid cancer, 5% to 20% in colorectal
cancer, and approximately 30% in ovarian cancer). Approximately 80% BRAF
mutations that happen in human neoplastic disorders are characterized by mutated
exon 15 resulting in the amino-acid V600E [1]. Such mutation imitates regulatory
phosphorylation which intensifies BRAF activity ten-fold versus wild-type BRAF [1].
The frequency of this activating mutation and the resultant oncogene addiction
makes mutated BRAF an extremely attractive target. Another putative RAF
inhibitor, sorafenib, has achieved regulatory approval. However, it lacks specificity
and potency against BRAF and its clinical activity is most likely due to inhibition of
other targets. Other BRAF inhibitors have recently entered clinical trials, although
vemurafenib was the first BRAF inhibitor that obtained FDA approval for BRAF
mutated refractory malignant melanoma.

16

Figure 1. The PTEN-PI3K-AKT-mTOR (mTOR) and RAS-RAF-MEK-ERK (MAPK)
signal axis. From Tsimberidou, Targeted Therapy in Translational Cancer
Research, 1st edition. Copyright 2015 by John Wiley & Sons, Inc. Published with
permission from Rightslink.
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As a proof-of-concept, BRAF inhibition has been effective in other
conditions as Hairy cell leukemia (Figure 2) [2] and Erdheim-Chester disease [3].
We attempted BRAF inhibition with vemurafenib in one patient from our
retrospective review of our database of patients with Erdheim-Chester disease
(Table 1) [3]; nevertheless therapy had to be halted due to toxicity. Haroche et al.
has found BRAF mutations in 54% of cases of Erdheim-Chester disease and
attempted BRAF inhibition in 2 patients with substantial and rapid clinical and
biological improvement [4].

Activating mutations specific to the MAPK pathway affect the BRAF, GNAQ,
and GNA11 genes (mutations frequently observed in melanomas and colorectal
cancer), whereas mTOR pathway-specific alterations include PTEN and TSC1/2
loss, as well as activating mutations or amplification of PI3K (observed in various
cancers). The mTOR and MAPK pathways are interconnected by homeostatic
feedback loops resulting compensatory activation of one of the pathways in
response to inhibition of the other. Cancer-driving receptor tyrosine kinases
(EGFR, HER2, cMET, c-KIT) and the downstream effector RAS signal through
both pathways simultaneously, and double mutations in the components of both
pathways and/or concurrent up-regulation are frequently observed in associated
tumors.

18

Figure 2. Pathology slides showing Hairy cell leukemia status post vemurafenib.
Bone marrow (panel A) displays hairy cells. Four months later, bone marrow
biopsy displays decreasing hairy cells from 68% (panel B) to 10-20% (panel C).
Originally published by the American Society of Clinical Oncology. Munoz J,
Schlette E, Kurzrock R. J Clin Oncol. 31 (20), 2013 Jul 10:e351-2. Published with
permission from Rightslink.
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Table #1 - Fourteen individuals with Erdheim-Chester disease (ECD) or Langerhan
cell hystiocytosis (LCH). Only patients with adequate follow-up were included.
Abbreviations: Central nervous system (CNS); female (F); male (M); radiation
(RT). Reprinted from Mayo Clin Proc, 89(7), Munoz J, Janku F, Cohen PR,
Kurzrock R. Erdheim-Chester disease characteristics and management, 985-96,
2014, with permission from Elsevier. Published with permission from Rightslink.
20

Therefore, as supported by the concept of synthetic lethality, simultaneous
inhibition of the MAPK and mTOR signaling cascades may lead to significantly
enhanced antitumor activity compared to inhibition of either cascade alone.
Indeed, preclinical data suggests simultaneous blockade of MEK and mTOR
substantially enhances antineoplastic action in different tumor xenografts as
prostate, colorectal, thyroid, pancreatic, and liver cancer. In vitro, cells carrying
dual mutated PI3K/KRAS show increased sensitivity to combined MEK plus mTOR
targeted agents.

These findings support the hypothesis that such combination therapy may
demonstrate activity for various indications, particularly tumor types characterized
by frequently occurring mutations in the respective pathways. The feasibility of
concomitant inhibition of MAPK and mTOR pathways is being actively explored
(http://clinicaltrials.gov), and includes trials of MEK inhibitors GSK1120212 and
AZD6244 combined with the mTOR inhibitors, everolimus and temsirolimus,
respectively. Furthermore, mutated PI3K and mutated members of MAPK have
been frequently found in neoplastic disorders.

For example, mutated PIK3CA coincide with mutated RAS, as KRASNRAS, and mutated BRAF. Janku et al. [5] showed that PIK3CA mutations
occurred in 54 (11%) of 504 patients tested; whereas mutated BRAF had been
reported in 31 (9%) of 361 individuals. BRAF mutations were seen in 44% (23/52)
of patients with melanoma. Regardless of histology, mutated RAS (KRAS, NRAS)
21

or BRAF had been reported in 47% of individuals with mutated PIK3CA versus
24% wild type PIK3CA. PIK3CA mutations were observed in 20% of individuals
with mutated RAS or BRAF versus 8% with wild type BRAF or wild type RAS [5].

Everolimus has the same mechanism of action as an immunosuppressant
and an antitumor agent. Everolimus works via inhibition of mTOR (mammalian
target of rapamycin) which is a protein kinase implicated in cell cycle control,
specifically cellular progression from the G1 to S phase. Furthermore, mTOR is
located downstream from PI3K and AKT. Then eIF4E-binding protein or 4E-BP1
and p70-S6-kinase (S6K) are located downstream from mTORand subsequently
translate and regulate mRNAs encoding proteins. The currently FDA approved
mTOR inhibitors are temsirolimus, which is intravenous, and everolimus, which is
oral.

The proposed trial seeks to establish the MTD of combined vemurafenib
plus everolimus in individuals with advanced resistant solid malignancies
characterized by the prevalence of MAPK and mTOR pathway alterations. In
addition to clinical safety evaluations, this study provide data regarding
pharmacokinetics regarding such combination. Pharmacodynamic activity and
preliminary evaluation of antitumor activity of the combination will be evaluated to
select indications for further development of the combination in phase II trials.
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The rest of this chapter named introduction is based upon: Munoz J, Janku
F, RAS-RAF-MEK pathway: Aberrations and therapeutic possibilities (Submitted
for publication, Book chapter, Targeted Therapy in Cancer, Wiley). The mitogenactivated protein kinases (MAPK) belong to a group of threonine- serine kinases
that form a cascade of molecular signals, eventually leading to proliferation,
survival, differentiation and cell fate determination [6].

The MAPK network is organized hierarchically (Figure 3) beginning with cell
membrane receptors subject to external stimuli (such as hormones, cytokines and
growth factors). These successively initiate proliferation from the cell membrane
to the nucleus as MAPK’s become phosphorylated by MAPK’s kinases (MAPKK’s),
which subsequently are phosphorylated by MAPKK’s kinases (MAPKKK’s) that
further become active via other kinases located the nearby cell membrane [6]. The
primary MAPK network is RAS:RAF:MEK:ERK [7] axis, composed by Rat Sarcoma
(or RAS), rapidly accelerated fibrosarcoma (or RAF), MAPK/ERK kinase (MEK);
plus

extracellular

signal-regulated

kinases

(ERK).

Once

up-regulated,

carcinogenesis is initiated. An inherited deregulated MAPK pathway, usually due
to heterozygous mutations [8], causes several phenotypic conditions marked by
cognitive defects, facial dysmorphism, cardiac defects, and an increased risk of
malignancies, known as the neuro-cardio-facial-cutaneous syndrome family [8].

Other components of this intricate network (Figure 3) include BRAF (or vraf
murine sarcoma viral oncogene homolog-B1) [9], whose designation stems from
23

the original identification of RAF during an exploration of retroviral oncogenes.
Initially RAF-1 was discovered (now called CRAF) in 1985, then ARAF in 1986,
and subsequently BRAF in 1988 [10].

Hierarchically, the apex of the cascade is composed of HRAS, KRAS, and
NRAS [10]. The next layer is formed by the MAPKKK, including ARAF, BRAF, and
CRAF. These can homodimerize or heterodimerize [10]. MEK1 and MEK2
compose MAPKK, which completes the network with ERK1 and ERK2, and MAPK
[10]. Although the MAPK network is generally shown as a linear path in cartoons
(Figure 1), in reality it branches out and interacts with molecular members of other
pathways including mTOR [11].

24

Figure 3. Simplified diagram of the MAPK signaling pathway. Following stimulation
of a cell-surface receptor (e.g., KIT), From Tsimberidou, Targeted Therapy in
Translational Cancer Research, 1st edition. Copyright 2015 by John Wiley & Sons,
Inc. Published with permission from Rightslink.

Germline mutations in the MAPK pathway are associated

with

developmental abnormalities [12]. Somatic mutations and acquired aberrations in
the MAPK pathway, particularly RAS and BRAF mutations, are associated with
malignancies [13]. For example, the MAPK pathway is activated in most
melanomas [14]. Furthermore, targeted therapy selectively or non-selectively
inhibiting those aberrations with small molecules has shown benefit [13]. Here, the
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currently known MAPK pathway mutations and therapeutic possibilities suggested
by these biomarkers are explicated.

Given the complexity of crosstalk among downstream signals, a working
hypothesis underlying this phase I study would be that BRAF plus mTOR blockers
will likely become synergistic. Additionally, combination therapy with drugs that
target different key signal transduction pathways may help overcome both intrinsic
and acquired resistance in individuals with prior exposure to RAS/RAF/MEK and/or
mTOR inhibitors. Furthermore, vemurafenib has been chosen as a BRAF inhibitor
because of its potency and there is ample evidence in the literature in BRAF
mutation positive metastatic melanoma to support its efficacy [15]. Additionally, its
strategic location at the top of the RAS:RAF:MEK:ERK (MAPK) axis is expected
to benefit and currently no RAS inhibitors are available. Of interest, pre-clinical plus
clinical trials show that combined BRAF plus mTOR inhibitors is efficacious,
especially in tumors with co-existing BRAF and PI3K/AKT/mTOR aberrations [1619].

Combining multiple agents with different mechanisms of action is now a
paradigm in oncology phase I clinical trials. Vemurafenib has received FDA
approval in the United States for treating refractory BRAF mutation positive
malignant melanoma and is being investigated in various other malignancies. The
RAS:RAF:MEK:ERK axis is very important when it comes to cell proliferation in
many human cancers. The frequency of this activating mutation and the resultant
26

oncogene addiction makes mutated BRAF an extremely attractive target. The
BRAF inhibitor vemurafenib has been selected as the backbone of this trial. The
mTOR inhibitors, such as everolimus and temsirolimus, are well known to exert
profound

anticancer

effects

across

malignancies

via

inhibiting

the

PTEN:PI3K:AKT:mTOR axis [20]. We hypothesize that combining a BRAF plus an
mTOR inhibitor may be synergistic and assist in overcoming resistance to single
agents

targeted

to

the

PTEN:PI3K:AKT:mTOR

(mTOR)

and/or

RAS:RAF:MEK:ERK (MAPK) signal axis. To our knowledge, there are no clinical
trials currently evaluating such combination. Therefore, we have designed a phase
one trial evaluating such combination in cancer patients.

BACKGROUND:

The RAS family: HRAS, KRAS and NRAS

The rest of this chapter named background is based upon: Munoz J, Janku
F, RAS-RAF-MEK pathway: Aberrations and therapeutic possibilities (Submitted
for publication, Book chapter, Targeted Therapy in Cancer, Wiley). The RAS (rat
sarcoma) genes were named because of the similarity of their sequences to the
Harvey rat sarcoma virus (or HRAS) and Kirsten rat sarcoma virus (or KRAS) [21].
Bos et al. [22] in 1989 reported RAS mutations in pancreatic adenocarcinoma
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(90%), colon cancer (50%), lung cancer (30%), and thyroid tumors (50%). KRAS
mutations occur most frequently (approximately 85%), then NRAS (approximately
15%), and HRAS (less than 1%). KRAS, NRAS and HRAS have a high degree of
homology and are expressed in many tissues. On average, somatic mutated RAS
ensue in as many as 30% of malignancies [22], although deregulated RAS
activation can occur without RAS mutation in the setting of up-regulated upstream
stimuli signal transducers or down-regulated downstream negative feedback.
These pivotal RAS molecules are small G proteins, or guanosine triphosphate
(GTP) / GTP-ases, frontline master regulators activating an intracellular network
of signals that ultimately lead to gene expression and proliferation. Small G
proteins also include RRAS, MRAS, Rap-2A, among others [23]. Guanine
nucleotide-exchange factors (GEF) remove guanosine diphosphate (GDP) from
inactive GDP-bound RAS. Consequently, RAS has a greater proclivity to bind to
the more prevalent GTP that then converts into its active form, GTP-bound RAS.
In summary, RAS proteins are governed via connecting to GTP and/or GDP, that
subsequently produces active or inactive proteins [24]. RAS proteins are tightly
regulated, due to a fined tuned balance between GDP/GTP switching, activators
such as GEF and natural inhibitors such as GTPase activating proteins (GAP).

RAS (HRAS:KRAS:NRAS) can carry aberrations that impair the alteration
or balance from GTP-active versus GDP-inactive form of RAS. From those
mutations, Gly12Val is the most frequent HRAS aberration in malignancies,
accounting for approximately 45% of total somatic HRAS gene mutations. The
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frequency of particular mutations depends on whether aberrations of a particular
gene are germline or acquired mutations. Interestingly, germline KRAS mutations
are rare in human malignancies; where acquired somatic KRAS mutations occur
far more frequently.

The congenital RAS-opathies: Germline mutations of RAS

A phenotypic spectrum is linked to a disturbed MAPK pathway causing
genotype-phenotype

associations

such

as

RAS

aberrations

[25]

and

neuro/cardio/facial/cutaneous disorders. These are known as RAS-opathies and
include Noonan syndrome [26] (predisposed to juvenile myelomonocytic
leukemia), LEOPARD [27], Neurofibromatosis type 1 [28] (predisposing individuals
to myeloid malignancies such as juvenile myelomonocytic leukemia), Costello
syndrome [29] (which can result in solid tumors such as rhabdomyosarcoma),
cardiofaciocutaneous syndrome [30, 31] (associated with acute lymphoblastic
leukemia), and other Noonan-like syndromes.

Each gene in the MAPK pathway, located on different chromosomes,
encodes a different protein so it is not surprising that different mutations manifest
clinically as different diseases [25]. The clinical presentation of these diseases is
not, however, exclusively associated with a particular mutation in these RAS-
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opathies. An example is the relatively common Noonan syndrome, which has been
associated with multiple MAPK aberrations (KRAS:NRAS:BRAF:MEK1). The son
of sevenless (SOS1) gene is a type of GEF, which as explained above, alters the
GDP/GTP balance involving RAS. Clinical overlap among these hyperactive RAS
syndromes [32] is likely due to an interplay among multiple members of MAPK.
Cardiofaciocutaneous syndrome were linked to a varied array of mutated
KRAS:BRAF:MEK1:MEK2 genes in as many as 90% of patients. One exception is
a germline missense mutated HRAS proto-oncogene causing confirmed Costello
syndrome in almost a 100% of affected patients. By the same token,
neurofibromatosis type 1 (NF1) is secondary to heterozygous NF1 gene loss-offunction, which regulates expression of neurofibromin, a RAS GTPase, a large
ubiquitous protein highly expressed in neurons, Schwann cells, and leukocytes
accounting for the clinical stigmata of neurofibromas. NF1 is a tumor suppressor
gene and patients are thus prone to second-hit malignancies as neurofibromin is
a protein with GAP activity (a negative controller of MAPK axis). Patients with type1 neurofibromatosis have more benign tumor development called neurofibromas
and malignancies such as peripheral nerve sheath tumors [33], sarcoma, GIST,
and other types of neoplasia [34], and juvenile myelomonocytic leukemia [28].
Costello syndrome can present with sarcomas, neuroblastoma, and other types of
neoplasia [29].

Even though the genotype-phenotype relationship is not completely clear
[12], mutations in KRAS affect the skin and may develop leukemia. Mutations in
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HRAS (such as Costello syndrome) manifest via skin abnormalities and tumor
growths. For example, patients with Noonan syndrome have a small increased
likelihood of developing malignancies [35]. LEOPARD syndrome has been
associated with leukemia, neuroblastoma, and melanoma [35, 36].

The acquired RAS-opathies: Melanoma and NRAS

Once a receptor is stimulated by cytokines or growth factors, the receptor
gets attached to Src homology 2 (SH2) domain that recruits SOS, subsequently
disrupting the homeostatic GDP/GTP balance. Cell receptor stimulation causes
RAS to dissociate from GDP and RAS binding to GTP, activating MAPK pathway
downstream components including RAF and MEK [37]. RAS activation is restricted
by GTP-ase activity or GAP’s that balances active-GTP-attached RAS versus
inactive-GDP-attached RAS. Mutations in RAS proteins change the amino-acids
(as G12:G13:Q61), modifying hydrolysis from the binding of RAS to GTP, thus
activating the MAPK pathway. BRAF mutations have been seen in 50 to 70% of
patients with melanoma [38, 39], whereas somatic NRAS mutations are found in
15-30% of cases, producing a constitutively active NRAS protein, which stimulates
the MAPK pathway. It has been suggested that an interaction exists between
NRAS and c-Met, epidermal growth factor receptor (EGFR), and KIT. Most patients
with melanoma have a hyperactive MAPK pathway; thus, it is not surprising that a
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MEK inhibitor such as MEK162 is associated with positive outcomes in NRAS
mutant melanoma.

RAF family: ARAF, BRAF, and CRAF

The ARAF:BRAF:CRAF proteins belong to the serine/threonine group of
kinases downstream from RAS, and upstream from MEK1/2. Even though
ARAF:BRAF:CRAF are siblings from a family, they have distinct characteristics;
BRAF would the powerful stimulator of MEK after comparison versus its relatives,
ARAF and CRAF. For example, BRAF and CRAF have essential differences in
binding to RAS [40] and are governed by distinct autoregulatory mechanisms [41].
Of the 3RAF isoforms, BRAF is most frequently involved in cancer (approximately
7% in general and 70% melanoma) [42]. Most mutated BRAF arise within the
kinase domain, leading to V600E substitute that stimulates MAPK [1]. Somatic
mutated

BRAF

were

commonly

documented

in

multiple

malignancies;

nevertheless aberrations in ARAF and CRAF are rarely seen. Despite the fact that
multiple mutated germline BRAF were documented, germline BRAF mutations
rarely promote tumorigenesis as they do not have the malignant potential of the
Val600Glu BRAF mutation. Interestingly, germline and somatic amino acid shifts
may up-regulate or down-regulate the mutant kinase.
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BRAF inhibitors

Regarding RAF in tumorigenesis, although BRAF is the main RAF subtype
overall such neoplasia characterize only a portion of malignancies. To further
complicate this picture, CRAF and BRAF can act in concert through
heterodimerization (Figure 3). Sorafenib, a RAF inhibitor that also blocks other
tyrosine kinases along with vascular endothelial growth factor, was not effective
treating patients with melanoma BRAF V600E mutations and phase three studies
did not endorse beneficial effects from adding sorafenib to standard of care [43,
44] despite initial promising results [45]. It may well be that other activated
pathways such as PI3K will need to be abrogated to produce a more beneficial
response [46]. Vemurafenib spearheads the list of approved BRAF inhibitors and
prolonged overall survival (6-month survival rates of 84% versus 64%) compared
to dacarbazine in BRAF V600-mutant melanoma randomized into the BRIM-3
study [15], results subsequently confirmed by an extended follow up [47]. Another
BRAF inhibitor, dabrafenib received FDA approval in U.S. (05/29/2013) to treat
BRAF V600E mutant melanoma [48]. The approval of dabrafenib was established
on improved progression-free survival (median 5.1 versus 2.7 months) compared
to dacarbazine in an international, open-label phase three study in 250 individuals
with BRAF V600E mutant melanoma [49].
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Management of melanoma in the era of B-RAF inhibitors

The management of early-stage high-risk cutaneous melanoma with local
resection plus adjuvant interferon alfa has been described elsewhere [50].
Managing metastatic melanoma is however more complicated. Despite the high
toxicity and low cure rate of high-dose interleukin-2, only recently have newer
agents revolutionized the management of metastatic melanoma such as the
immunotherapy ipilimumab, the monoclonal antibody directed against CTLA 4, or
a targeted therapy as vemurafenib (FDA approved if there is a V600 driver mutant
in the BRAF gene, which is present in approximately 50% of patients) [51, 52]. This
approval was based on clinical trials demonstrating prolongation of overall survival
in this population. The replacement of glutamic-acid by valine at amino-acid 600
or V600E mutation was found in approximately 80% of cases [52]; whereas the
substitution of lysine for valine (V600K mutation) was shown in 20% of cases.

To date, no randomized comparison has been undertaken between
immunotherapy with ipilimumab, high-dose interleukin-2 and BRAF inhibitors or
the appropriate sequencing of such agents. Nevertheless, it is indicated that all
patients be assessed, minimally for BRAF mutation, or to test for a more
comprehensive panel of mutations. If a comprehensive mutational evaluation is
not available, in the absence of BRAF V600E mutation, screening for non-V600E
BRAF mutations, other MAPK aberrations (e.g., NRAS) and KIT should be done.
Just as distinct malignancies based on their organ of origin have different
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frequencies of a particular aberration (Figure 4) [1]; there are particular phenotypic
characteristics that correlate with the genotype of patients with melanoma [53]. As
an example, an acral melanoma may carry a KIT mutation (approximately 15-20%)
instead of a BRAF mutation. Initial phase two trials of imatinib for unselected
metastatic melanoma showed limited activity [54-56]; nevertheless a subsequent
phase two trial with selected individuals harboring a KIT mutation or amplification
showed 23.3% response [57]. The MAPK pathway and microphthalmia-associated
transcription factor (MITF) were associated in melanocyte differentiation/survival
[58, 59]. MITF is phosphorylated by the MAPK pathway [60] and MITF mutation
has been associated with familial and sporadic melanoma [61]. In addition to MITF,
specific aberrations have been correlated with particular subtypes of melanoma
such as BRAF/NRAS in conjunctival melanomas (BRAF mutations in 29% and
NRAS mutations in 18%) [62], KIT mutations or amplifications in acral (36%) and
mucosal (39%) melanomas [63], and GNAQ/GNA11 in uveal melanomas (GNAQ
in 45% and GNA11 in 32%) [64] (Figure 4). Furthermore, BRAF mutations are
common in vertical growth phase melanoma and metastatic melanoma (62-72%)
[65], whereas BRAF mutations are rare in radial growth phase melanomas (10%)
[65] or in in situ melanoma (5.6%) [66]. Finally, mutated BRAF has been reported
in non-malignant growths (82% in nevi) [9, 66] suggest that BRAF mutations are
involved in collaboration with other molecular aberrations in carcinogenesis rather
than being solo founder mutations. As an example, mutant BRAF had been
reported in 29% of invasive melanoma versus 5.6% of in situ melanomas. Mutant
NRAS had been described in 5.2% of primary melanomas and in no in situ
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melanomas [66]. These NRAS & BRAF mutations seem to occur prematurely
during melanoma-genesis while remaining present during worsening of disease
[14].

Figure 4. Genotypes and phenotypes of malignancies expressing BRAF
mutations. From Tsimberidou, Targeted Therapy in Translational Cancer
Research, 1st edition. Copyright 2015 by John Wiley & Sons, Inc. Published with
permission from Rightslink.
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Comorbidities, performance status, drug toxicities, pace of disease
progression, and presence of brain metastases are factors to be considered in
choosing the appropriate course of therapy. For example, unfit patients with fastpaced bulky disease and central nervous disease involvement are unlikely to
benefit from high-dose interleukin-2, although BRAF inhibition can salvage
patients in that scenario. Ipilimumab, an antibody-based immunotherapy directed
against the CTLA-4 checkpoint, may need a prolonged period of time to show
activity, and would not be appropriate in the setting aggressive disease
progression. In contrast, BRAF inhibitors are a very attractive targeted therapy in
melanoma. Both vemurafenib [67, 68] and dabrafenib [69, 70] have reported
activity with melanoma that invaded the central nervous system.

CRAF story

Downstream RAS, such next line of activated molecules includes BRAF and
CRAF. No reports of activating mutations of CRAF have been documented so far,
whereas BRAF kinase domain mutations are as common as 50% in melanoma.
As a result, it has been suggested that there is single-step activation between RAS
and BRAF, but that multiple-steps might be involved between RAS and CRAF [71].
BRAF inhibitor drugs abrogate MAPK in mutated BRAF cell lines, whereas BRAF
inhibitors may paradoxically stimulate the MAPK pathway within wild-type BRAF
cells [72-74]. Despite being relatively safe, dermatologic toxicity [75] was seen with
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these inhibitors. These include cutaneous squamous cell carcinoma in 12% [76],
sometimes developing within weeks of starting a BRAF inhibitor suggesting
preexisting RAS mutations in other skin areas due to paradoxical activation of the
MAPK pathway (HRAS mutations in 41% of 29 samples with cutaneous squamous
cell carcinoma or keratoacanthomas) [77]. It has been suggested that combining
a MEK inhibitor and a BRAF inhibitor may decrease toxicity caused by paradoxical
stimulation of MAPK axis. As a more ominous complication, a patient exposed to
vemurafenib developed fast worsening of chronic myelomonocytic leukemia
related to mutant RAS [78].

Primary and secondary resistance to BRAF inhibitors

Despite high initial responses as high as 48% [15], primary and secondary
resistance to vemurafenib has been reported and most melanoma patients
exposed to vemurafenib eventually develop resistance (Figure 5). Thus,
combinatorial trials using BRAF inhibitors as a backbone or small molecules
targeting other areas of the MAPK pathway are suggested to overcome resistance.
Tissue samples obtained during the phase two BRIM2 study showed an
association between decreased ERK phosphorylation and objective responses,
whereas increased ERK phosphorylation and the development of secondary
NRAS (Q61) or MEK1 (Q56P) or MEK1 (E203K) mutations were associated with
acquired resistance [79].
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Thus, re-stimulation of MAPK seems to develop resistance to drugs that
abrogate BRAF. Interestingly, resistance hasn’t been linked with developing a
second mutation that impairs drug binding to BRAF, a mechanism observed in
other malignancies. Other possible mechanisms that can cause resistance include
MAPK pathway reactivation via alternative means like insulin growth factor
receptor-1 (or IGF-1R)/PI3K axis activation [80, 81], PD-L1 expression [82],
increased cyclin D1 expression [83], elevated CRAF protein levels [84], production
of shortened forms of BRAF proteins due to aberrant RNA splicing [85], NRAS
(Q61) mutations [79], MEK1 (Q56P, E203K, C121S, or F129L) mutations [79, 86,
87], and ERK activation through bypassing mechanisms including COT activation
and receptor tyrosine kinase as PDGFRβ upregulation [88, 89]. Conversely,
clinical

response

associated

with

BRAF

inhibition

lead

to

decreased

phosphorylated ERK levels [90].
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Figure five. Mechanistic diagrams regarding resistant malignant cells to BRAF
inhibition. From Tsimberidou, Targeted Therapy in Translational Cancer Research,
1st edition. Copyright 2015 by John Wiley & Sons, Inc. Published with permission
from Rightslink.
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MEK inhibitors - The MEK family: MEK1 and MEK2

RAS activation is followed by activation of RAF (ARAF:BRAF:CRAF),
subsequently MEK (MEK1A1/MEK1A2), then finally ERK (ERK1:ERK2). ERK is
the final step of the pathway and acts upon multiple proteins. MEK1:MEK2 genes
encode kinases that activate ERK proteins, their only known substrate. MEK
kinase activity has been documented as inducing proliferation, although no MEK
mutations have been associated with triggering development of cancer or primary
resistance to vemurafenib. Interestingly, a MEK1 C121S mutation was recently
seen in a melanoma case that became vemurafenib-resistant. The mutant had not
been present before vemurafenib therapy, supporting the role of molecular
evolution in therapeutic resistance. MEK aberrations have however been linked to
some neurocardiofacialcutaneous syndromes. In melanoma, the BRAF V600E
mutation correlates with response to MEK inhibitors in preclinical models and
clinical studies. Trametinib abrogates MEK1/MEK2 in patients with prior anti-BRAF
therapy for mutant BRAF V600E/V600K [91]. Trametinib (2 mg/day orally) was
FDA approved based on improved PFS (median 4.8 versus 1.5 months) and
overall survival (6-month survival rate of 81% versus 67%) compared to
chemotherapy (dacarbazine or paclitaxel) in the phase 3 METRIC study in 322
individuals that have BRAFV600E–positive advanced melanoma [92]. Individuals
status post chemotherapy or immunotherapy were included, whereas prior BRAF
inhibitors were not allowed and no responses to trametinib were observed [93].
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Trametinib received FDA approval [91] when combined with dabrafenib for
initial treatment for mutant BRAF V600E/V600K melanoma. Overall response with
dabrafenib (150 mg) combined with trametinib (1 or 2 mg) had been reported as
76% versus 54% with single agent dabrafenib (P=0.03) [94]. Squamous cell skin
cancer developed not as frequently in the dual drug group compared to
monotherapy (7% versus 19%), whereas pyrexia developed more often in the dual
drug combination versus monotherapy (71% versus 26%) [94].

Other MEK inhibitors under development are selumetinib, MEK162 and
others [95]. The combination of selumetinib plus dacarbazine was compared to
single-agent dacarbazine in a phase 2 study with randomization that accrued 91
BRAF mutant individuals, showing improved progression-free survival (5.6 versus
3.0 months) but not an improvement in survival [96]. Furthermore, a phase II trial
assessed MEK162 in 71 individuals with melanoma carrying V600 BRAF (41
cases) or NRAS mutations (30 individuals) with partial response of 20% in both
groups (8/41 cases in BRAF mutations plus 6/30 patients in NRAS mutations) [97].

ERK inhibitors
A novel selective ERK1/2 inhibitor SCH772984 that may work in cases
resistant to BRAF or MEK inhibitors while producing improvement in xenografts
[98]. Further data regarding ERK inhibition is eagerly awaited.
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Implications of aberrations in the MAPK pathway in the management of lung
carcinoma

Personalization of genotype-driven treatment for metastatic lung cancer is
promising with multiple driver mutations have been identified such as EGFR, ALK,
ROS1, BRAF, NRAS, KRAS, among others. BRAF mutants have been reported in
1-3% of patients with NSCLC [99-101]. The trial testing dabrafenib in BRAF V600E
metastatic NSCLC is ongoing (NCT01336634). NRAS mutations were seen in less
than 1% (1 of 195) of NSCLC [102]. KRAS mutants seem to be more common in
smokers [103]. KRAS mutations were seen in 22% of smokers with lung
adenocarcinomas, whereas transition KRAS mutations were seen in 15% of nonsmoker patients with lung adenocarcinoma [104]. The effect of mutated KRAS on
300 of 1,543 individuals with early NSCLC status post adjuvant chemotherapy
following resection didn’t show a statistically significant differences in survival
versus wild-type KRAS in pooled-analysis of four clinical studies [105]. In the
metastatic setting, mutated KRAS conferred a worse prognosis compared to
mutated EGFR [106], whereas KRAS mutation was prognostic for reduced PFS in
the ones that received erlotinib-maintenance although didn’t show statistically
significant difference in survival compared to wild-type KRAS [107]. KRAS
mutations herald patients with colon malignancies that are resistant to cetuximab.
Nevertheless, responses to cetuximab were maintained in phase 3 studies of
NSCLC [72, 108]. In the absence of current KRAS targeted drugs, the therapeutic
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emphasis for KRAS-mutant lung carcinoma is to target molecules located downstream from activated KRAS, which is supported in pre-clinical models [18].
Objective responses had been documented in 16/43 individuals (37%) status post
docetaxel plus selumetinib compared with none of 40 KRAS-mutated individuals
with advanced NSCLC receiving docetaxel plus placebo [109]. Clinical trials
evaluating MEK inhibitors combined with chemotherapy in KRAS-mutated NSCLC
are underway (NCT01192165, NCT01362296).

Acquired mutations in the MAPK pathway in other malignancies

Broadly stated, RAS mutations are present in as many as 30% of all
malignancies [10], whereas BRAF mutations are found in as many as 60%
(melanomas 60%; thyroid neoplasia 50%; colon malignancies 20%) [10].
Activating RAS oncogenic mutations (NRAS, HRAS and KRAS in decreasing
frequency) are more frequently seen in follicular-subtype thyroid neoplasia (80%)
than papillary-subtype thyroid cancer (20%) [110]. RAS mutations have been
linked to worse outcome in thyroid neoplasia [111]. On the other hand, 43.8% of
500 patients with papillary thyroid cancers were found to have BRAF mutant state,
which were linked to higher invasiveness [112]. The BRAF V600E mutation has
been linked with high-risk clinicopathological factors [113] and increased cancerrelated mortality in individuals with papillary-subtype thyroid cancer [114]. BRAF
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inhibitors explored in preclinical mice models of thyroid carcinoma decreased
levels of phosphorylated MEK and ERK [115].

Erdheim-Chester disease (ECD) has been felt to be characterize as nonLangerhans cell histiocytosis. Because it could co-exist in the setting of
Langerhans histiocytosis [116, 117], it is believed that these conditions may
overlap pathologically and therapeutically [118]. BRAF mutations were found 54%
(13/24) of patients with Erdheim-Chester disease and [4] in 38% (11/29) to 57%
(35/61) of patients with Langerhans cell histiocytosis [119, 120]. Subsequently,
three patients with relapsed mutated BRAF V600E Erdheim-Chester disease
displayed positive outcomes status post BRAF inhibitor vemurafenib [121].
Individuals with classic hairy cell leukemia almost always carry the V600E BRAF
mutation [122], whereas approximately 50% of variant hairy cell leukemia carry
MAP2K1 gene (encoding MEK1) mutations [123] instead of BRAF mutations [124].
Some have suggested that patients with exon 15 BRAFV600E-negative hairy cell
leukemia should be screened for exon 11 (F468C and D449E) mutations [72].
Case reports of clinical improvement after exposure to the BRAF inhibitor
vemurafenib have been described [72, 125] and clinical studies are in progress to
determine the protagonist part of BRAF inhibition for hairy cell leukemia
(NCT01711632). BRAF kinase mutants have been documented in 4% of multiple
myeloma [126]. The case report of an individual with mutated BRAFV600E multiple
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myeloma documented response to low-dose BRAF inhibition with vemurafenib
[127].

Big results for small molecules

Although aberrations in the MAPK pathway have been known to contribute
to deregulated growth, both in inherited developmental disorders and acquired
mutations, rendering patients prone to malignancies, only until recently have
inhibitors been developed that match their respective targets. Initial investigations
on the MAPK pathway were based on pre-clinical models of acute growth factor
exposure in the lab, which do not correlate with a normal physiological state in
vivo, hence, the utility of MAPK pathway inhibitors is being tested in the clinic and
the challenges of developing a state of BRAF inhibitor resistant disease need to
be studied (Figure 4). Three agents have been approved by the FDA for use in
BRAF-mutant metastatic melanoma, the BRAF blockers (vemurafenib &
dabrafenib) and the MEK blocker (trametinib). Further exploration of MAPK
inhibition in other malignancies is eagerly awaited. Molecular stratification, and
targeted therapy of the MAPK network poses us for success while offering the
opportunity to launch a decisive attack against cancer.
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PATIENTS AND METHODS:

Patient Eligibility:

Inclusion Criteria:

-

Confirmed BRAF mutated status.

-

Measurable or non-measurable disease.

-

Individuals with advanced cancer.

-

Refractory to standard of care.

-

Three weeks post prior treatment.

-

ECOG better than two.

-

Adequate organ and marrow as per standard (e.g. ANC>1.0).

-

Contraception if needed during and thirty days post study.

-

Able to understanding/signing/consenting our study.

Exclusion Criteria:

-

Poorly controlled additional conditions.

-

Poor organ function (e.g. creatinine worse than 2.0).

-

Pregnancy.

-

Status pot stem cell transplantation.
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-

Allergy to vemurafenib or everolimus.

-

Recent surgical procedure (within a month).

-

Patients with a baseline QTc > 500 ms.

Treatment Plan:

This is a phase one, single hospital, open-label, dose-escalation trial of
vemurafenib plus everolimus, dosed in combination to individuals with metastatic
or advanced solid malignancies. Dose escalation for such study will examine
eligible patients with various tumor types. The study will be piloted at the MD
Anderson Cancer Center in Texas. Other premedications may be substituted or
not used at all based on physician discretion. Patients will continue treatment
until their disease worsens, their side effects become too severe, the patient’s
physician feels we shouldn’t continue, or election to withdraw from study. A
patient may also be discontinued due to a concurrent illness that prevents further
administration of treatment. Premedication, precautions, route, and schedule for
each medication are described in the tables below. Each study medication in this
protocol has been approved by the FDA and is commercially available. Other
investigational drugs beyond vemurafenib and everolimus are not allowed.

Concomitant medications:

Vemurafenib plus everolimus will be the only chemotherapy drugs (or
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agents used with anti-neoplastic intent) given in this study. No other
chemotherapeutic or anticancer agents may be administered. Individuals will not
enroll in other clinical protocol that administers a treatment or uses a device as
treatment while enrolled in this study except for supportive care trials. Irradiation
is not allowed during the study, except for palliation purpose at the discretion of
the Investigator. Administration of other chemotherapy, immunotherapy or
antitumor hormonal therapy during the study is not allowed. Supportive care,
including, but not limited to, antinausea drugs can be administered if approved by
the treating physician. Because all the agents are commercially available and
are FDA approved drugs, all institution standard guidelines for these drugs may
be used as per treating physician. Concurrent treatment with bisphosphonates is
allowed for patients who received stable doses prior to study entry. All
concomitant treatments, including blood and blood products, must be
documented and recorded. Erythropoietin may be administered as per treating
physician consistent with local guidelines. Granulocyte stimulating factors should
be administered according to institutional guidelines. As the proposed agents in
this trial have extensive metabolism through the CYP450 3A4 substrates,
patients should have a 5 half-life washout period or 4-week washout period,
whichever is shorter, prior to receiving the investigational agents.
Overlapping toxicities for vemurafenib plus everolimus: Headache (1837%). Peripheral edema (15-40%). Rash (20-50%). Diarrhea (20-45%). Fatigue
(10-30%). Abnormal liver function tests (20-60%).
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Study schema:

Table 2. Dose-escalation schedule for vemurafenib plus everolimus (28-day
cycle). The starting dose level is Level 1. If all patients tolerate dose Level 1,
then we will dose escalate to dose Level 2. However, if dose Level 1 is
intolerable, then we will de-escalate to dose Level -0. If dose Level 0 is
intolerable, then we will de-escalate to dose Level -1.

Pretreatment Evaluation:

-

Complete history and physical examination within 2 weeks of C1D1.

-

12-lead ECG within 4 weeks of C1D1. Vemurafenib can cause Qtc

prolongation and monitoring is recommended as per package insert.
-

Laboratory studies: CBC with differential, BUN, creatinine, potassium,

magnesium, total bilirubin, SGPT [ALT], glucose, triglyceride, cholesterol, and
urine pregnancy test. Dyslipidemia is a known side effect of everolimus and
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needs to be monitored as per package insert.
-

Radiologic evaluation of measurable disease and pertinent tumor markers

within four weeks before starting treatment. If the patient does not have
radiologically measurable disease but has cutaneous measurable disease, this
must be documented at the pretreatment evaluation physical examination.

Evaluation during study:

-

Physical examinations at least once per cycle (28 days). This includes

skin examination every 2 cycles.
-

Labs should be performed at least once per cycle including CBC with

differential, BUN, creatinine, potassium, glucose, triglycerides, cholesterol, total
bilirubin, and SGPT [ALT].
-

Radiologic evaluations and pertinent tumor markers will be repeated after

two cycles of treatment.
-

ECGs monthly for three months then q3 months.

Evaluation of Toxicity:

-

The MTD will be defined by DLTs that occur in the first cycle (induction

phase). All enrolled participants will be considered in the DLT analysis.
Neupogen/neulasta are allowed in this trial. Correctable electrolyte imbalances
and alopecia are not considered DLTs.
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-

Three individuals will be dosed per level. If there are no side effects, the

next cohort will be treated with a 100% increment. If there is Grade 1 toxicity, a
50% increment will occur. If there is Grade 2 toxicity, a 25% increment will occur.
If there is Grade 3 or 4 toxicity due to study drug, there will be an expansion to
six patients. If no other individuals have Grade 3 or 4 side effects, then next
cohort will be treated with a 25% dose increase. If a second patient has Grade 3
toxicity, then the MTD is exceeded. The next lower dose level will be expanded
to six patients. The MTD is the highest level with less than 1/6 individuals with
Grade 3 or higher toxicity.
-

Patients will continue on the study until their disease has progressed, they

elect to come off the study, they experience toxicities that warrant coming off
trial.
-

No maximum number of cycles if benefiting clinically.

-

If a response has been observed in a particular tumor type with the study

drug or drug combination, then the study may be expanded to include a total of
14 participants with that tumor type. All enrolled participants will be considered in
the DLT analysis.
-

Up to 3 additional patients may be added to a cohort for evaluation of

correlative studies.

Response Criteria:

While primary objectives of this study include the evaluation of dose-ranging
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experience and the toxicity observed, an attempt to evaluate efficacy will require
the following criteria for response. Patients with lymphoma will be measured per
the CHESON criteria and all others will be evaluated with the RECIST criteria.
For details of the CHESON criteria and RECIST criteria, please see Appendix A.

Criteria for Removal from the Study:

-

If a Progression of disease per WHO or RECIST criteria as described

previously. (Exception: If the patient is deriving clinical benefit).
-

The development of unacceptable toxicity.

-

Physician recommendation for patient removal.

-

Patient elects to discontinue further treatment on the study medications.

Reporting Requirements:

Evaluation of Toxicity/Adverse Events: Evaluation of toxicity during the conduct
of the study will be done following the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (CTCAE). Known grade I and II toxicities
and all clinically insignificant toxicities will not be tabulated for FDA approved
drugs. The study uses FDA approved agents with known toxicity profiles.
Therefore, Grade 1 and 2 toxicities (related or unrelated) will not be collected or
documented as these are not considered clinically significant in this patient
population and/or they are expected for these study agents. Grade 3 and 4
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toxicities that are felt to be treatment related and unexpected (per package
insert) will be documented. Unless otherwise documented in the electronic
medical record as clinically significant and study drug related, all lab
abnormalities will be assumed to be related to the patient’s other co-morbid
conditions, prior therapies, other concomitant therapies/medications, or
underlying cancer. Serious Adverse Events will be reported per standard IRB
reporting requirements. Serious Unexpected problems will be reported per
standard IRB reporting requirements. Assessment of Intensity: Maximum
intensity should be assigned to an adverse experience. Intensity will be assigned
a Grade of 1-5. Final arbitration of intensity in cases of differing assessments by
different practitioners will be the attending physician. Day to day fluctuations of
intensity may not be recorded but rather the worst grade over the longest time
period.

Statistical Considerations:

-

This is a descriptive study with no formal statistical hypothesis to test.

-

This protocol will utilize a standard 3 + 3 design.

-

If a response has been observed in a particular tumor type with the study

drug or drug combination, then the study may be expanded to include a total of
14 participants with that tumor type. All enrolled participants will be considered in
the DLT analysis. If at any time more than or equal to one-third of the
participants at a level develop DLT, that dose is above MTD.

54

-

Patients can be added at the highest dose level seemed safe to date. All

patients are considered in the DLT analysis. Up to 3 additional patients may be
added to a cohort for evaluation of correlative studies. These patients will be
considered in the DLT analysis.
-

There will be no intra-patient dose escalation.

-

Expected sample size. Approximately up to 35-45 patients will be treated

in this study including patients treated in dose expansion cohort at MTD. The
estimated accrual rate is 1-3 patients per month.

Dose Delays and Modifications:

-

If Grade 3 toxicity occurs (DLT), dose reduction by 50% is allowed after

patient recovers. The drug that will be reduced is the one that the physician feels
has most likely caused the toxicity. If the drug that caused the toxicity is not
known, the patient will be dose reduced to the previous dose level.
-

If Grade 3 o/4 toxicity that is known to be related to one drug in the

regimen, then that drug may be de-escalated to the prior dose level after the
patient recovers to </= Grade 1 toxicity.
-

If Grade 3/4 toxicity for which it is unclear which drug is the cause of the

toxicity, then the drug which was dose escalated at the current dose level may be
de-escalated to the prior dose level after the patient recovers to </= Grade 1
toxicity.
-

If Grade 3/4 toxicity at level one, and if the toxicity is known to be related
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to one drug in the regimen, then a dose reduction of 50% of that drug is
permitted after the patient recovers to </= Grade 1 toxicity.
-

If Grade 3/4 toxicity at level one, and if it is unclear which drug is the

cause of the toxicity, then a dose reduction of 50% of all drugs in the regimen is
permitted after the patient recovers to </= Grade 1 toxicity.

Correlative Studies (optional):

This phase I study will utilize novel technologies to analyze key
downstream pathways efficiently so as to provide high impact data that may
further expand our understanding of the biology of BRAF activation. Two major
pathways appear to be involved in downstream signaling. The PI3K [128] and
the MAPK axis are involved in proliferation and cell cycle progression.
Aberrations in the PI3K/AKT/PTEN/RAF/RAS/GNAQ and related pathways may
be assessed in tumor tissue or circulating blood.

Calendar:

Baseline assessment led within 14 days before C1D1. Baseline screening
imaging can take place up to 4 weeks before the protocol starts. If screening
procedures were performed within 7 days prior to Cycle 1 Day 1 it may be
counted as baseline visit and Cycle 1 Day 1 labs and exams may not have to be
repeated. Routine lab studies, physical exams, vital signs, weight, performance
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status and scans will have a flexibility window of +/- 7 days.

Table 3. Study calendar.

•

Physical examinations at least once per cycle. ECG at least once per

cycle per vemurafenib’s package insert.
•

Labs should be performed at least once per cycle including CBC with

differential, BUN, creatinine, potassium, glucose, triglycerides, cholesterol, total
bilirubin, and SGPT[ALT].
•

Radiologic evaluations and pertinent tumor markers will be repeated after

two cycles of treatment.
•

Testing and drug administration will take place as per protocol schedule

unless patient/logistical/medical reasons intervene.
•

Note: Evaluation that can occur once per cycle can be done at any point in
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the cycle.

PRELIMINARY RESULTS:

This study has so far enrolled 10 patients as of April 2014 (Table 4). The most
common diagnosis was melanoma in 5 out of 10 patients (50%). Male patients in
7 out of 10 patients (70%). The average age was 63.5 years. The average
number of cycles on study was 3.2 and the average duration on study was 102.8
days. All patients had BRAF mutations (Table 5), particularly BRAF V600E
mutation in 8 out of 10 patients (80%). Two out of the 10 patients (20%) had
partial responses and additional 2 out of the 10 individuals (20%) displayed
stability on imaging studies. Five patients out of 10 (50%) had received
vemurafenib previously (Table 6). The two patients that displayed partial
responses did not have melanoma (they had papillary thyroid cancer and
NSCLC, respectively) with none of them had not received vemurafenib
previously. The 77-year-old male with papillary thyroid carcinoma was
chemotherapy and BRAF inhibitor naïve prior to receiving vemurafenib plus
everolimus displaying a 36% response as per RECIST 1.1 (Figure 6). The 55year-old female with NSCLC status post multiple lines of chemotherapeutic
agents and also the BRAF inhibitor dabrafenib prior to starting vemurafenib plus
everolimus displaying a 39% response as per RECIST 1.1 (Figure 7).
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Case

Diagnosis

Age

Gender

Dose (mg)

Cycles

Duration (days)

Response

1

Melanoma

65

M

720/5

8.00

224.00

SD

2

Melanoma

68

M

720/5

3.00

96.00

PD

3

Melanoma

45

F

720/5

2.00

57.00

PD

4

Colorectal

63

M

720/5

3.00

99.00

PD

5

Melanoma

77

F

720/5

1.00

45.00

PD

6

Appendix

78

M

720/5

5.00

154.00

SD

7

NSCLC

55

F

720/10

4.00

132.00

-39%

8

Melanoma

66

M

720/10

1.00

30.00

PD

9

Esophagus 41

M

720/10

1.00

49.00

PD

10

Thyroid

M

720/10

4.00

142.00

-36%

77

Table 4. Characteristics of patients enrolled. M: Male. F: female. SD: Stable
disease. PD: Progressive disease. Cycles: Number of cycles. Response: Best
response. Appendix: Appendicular carcinoma. Thyroid: Papillary thyroid
carcinoma. NSLCL: non-small cell lung cancer.
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Case

Response Mutation analysis

1

SD

BRAF V600E

2

PD

BRAF V600K, MET T1010I

3

PD

BRAF V600E

4

PD

BRAF V600E, SMAD4 P356R, TP53 R213*, KIT M541L

5

PD

BRAF V600E, CDKN2A R58*, PIK3CA E545K, MET N375S

6

SD

BRAF V600E, TP53 R110L

7

-39%

BRAF V600E, IDH1 R132C, PPP2R1A R183

8

PD

BRAF V600E, KIT M541L

9

PD

BRAF Q609*, KRAS A146P, FBXW7 S478F, KIT G498S, KIT M541L,
STK11 D23E

10

-36%

BRAF V600E, PIK3CA H1047R, RET Q626K

Table 5. Relationship between responders and mutational status. Response:
Best response. SD: Stable disease. PD: Progressive disease.
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Case

Response Previous therapies

1

SD

Cisplatin, vinblastine, and dacarbazine; vemurafenib

2

PD

Dacarbazine, vinblastine, cisplatin, IL-2

3

PD

Cisplatin, bendamustine, dacarbazine; ipilimumab; IL2;
carboplatin, paclitaxel; vemurafenib

4

PD

FOLFOX, bevacizumab; FOLFIRI, cetuximab; mitomycin-C;
FOLFIRI, cetuximab; vemurafenib

5

PD

Vemurafenib; trametinib and dabrafenib

6

SD

FOLFOX; FOLFIRI

7

-39%

Carboplatin, paclitaxel; erlotinib; pemetrexed, rituximab;
vinorelbine; gemcitabine; dabrafenib; MDX 1105 (anti-PD-L)

8

PD

Temozolomide, ipilimumab; GSK1120212 (MEK inhibitor);
vemurafenib; vemurafenib and sorafenib; carboplatin, paclitaxel

9

PD

Docetaxel, fluoracil, oxaliplatin; irinotecan, cisplatin

10

-36%

Radiation

Table 6. Relationship between responders and previous therapies. Response:
Best response. SD: Stable disease. PD: Progressive disease. IL-2: Interleukin 2.
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Figure 6. The 77-year-old male with papillary thyroid carcinoma was
chemotherapy and BRAF inhibitor naïve prior to receiving vemurafenib plus
everolimus displaying a 36% response as per RECIST 1.1.
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Figure 7. The 55-year-old female with NSCLC status post multiple lines of
chemotherapeutic agents and also the BRAF inhibitor dabrafenib prior to starting
vemurafenib plus everolimus displaying a 39% response as per RECIST 1.1.
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DISCUSSION:

Searching under the street light:

We have been looking for diagnostic and prognostic cues “where the light
is” for the longest time in many fields in medicine including oncology. Old age
and elevated lactate dehydrogenase helped us to understand some conditions
although most patients were still treated blindly with non-targeted cytotoxic
chemotherapy in the absence of better stratification models. Cytogenetics, able
to assess large chromosomal structure deviations, heralded a step forward. At
the end of the day, a very small group of patients respond dramatically to nontargeted cytotoxic chemotherapy in most malignancies when we are shooting in
the dark; whereas a relatively larger group of patients respond to matched
targeted treatments while avoiding therapeutic misses or near-misses under the
bright shining light of molecular profiling. Time and scientific progress brought
upon us multiple novel molecular profiling platforms that have facilitated the
process of finding the right treatments for the right subgroups of patients. As a
disclaimer, some profound responses seen in the targeted era are short-lived
and perhaps combinatorial trials will overcome therapeutic resistance in the
years to come.

Cancer is not only one disease. For example, ALK altered neoplasia
("ALK-oma") is approximately four percent of lung carcinoma. Matching drugs to
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targets showed impressive results, albeit brief, hence it has been suggested that
combination therapy will be needed to overcome resistance to single agents
[129].

Targeting the MAPK & mTOR: MAPK is a group of serine/threonine
kinases that form a cascade of molecular signals that eventually lead to
proliferation, survival, differentiation and cell fate determination. The MAPK
network is organized hierarchically starting at the level of the cell membrane
receptors with external stimuli (as hormones, cytokines and growth factors)
successively communicating a message of proliferation all the way to the nucleus
as MAPK’s, MAPKK’s, and MAPKKK’s. The main identified MAPK network is the
pathway conformed by RAS-RAF-MEK-ERK, and, if up-regulated, it leads to
carcinogenesis. Inherited deregulated MAPK pathway, usually due to
heterozygous mutations, cause several phenotypic conditions [130] with
cognitive defects, facial dysmorphism, cardiac defects, and increased risk of
malignancies; coined as neuro-cardio-facial-cutaneous syndrome family. Other
players in this intricate network include BRAF with a designation which stems
from its original identification of RAF during retroviral oncogenes. Initially RAF-1
was discovered (now called CRAF) in 1985, then ARAF in 1986, and
subsequently BRAF in 1988. Hierarchically, the top of the cascade is aligned by
HRAS, KRAS, and NRAS. The next layer is formed by the MAPKKK including
ARAF, BRAF, and CRAF that may homodimerize or heterodimerize. MEK1 and
MEK2 line up as MAPKK to culminate the network into ERK1 and ERK2, the
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MAPK. Despite the fact that we illustrate the MAPK network as a linear path, it
actually branches out and interacts with molecular members of other pathways
including mTOR.

Novel molecular testing - Coming of age:

Morphologically, many tumors look alike (i.e. some aggressive lymphomas,
Ewing sarcomas or desmoplastic small round cell tumors) and, let alone, light
microscopy would have major difficulties settling this diagnostic matter.
Diagnostic tools to detect molecular aberrations may detect specific mutations
already known to be common in a particular malignancy or find previously
unidentified mutations. Molecular diagnosis include new-comers as transcriptome
sequencing and proteomics that may also permit the identification of novel
biomarkers for targeted treatments.

Prognostication - Is LDH still valuable in the molecular era?

Definitively yes (at least at present). Molecular tools are not meant to
replace clinical and laboratorial variables but rather supplement and enrich the
information available at reach in each particular case. The ubiquitous elevated
lactate dehydrogenase (LDH) is a poor’s men prognosticator in both benign (i.e.
pancreatitis) and malignant (i.e. lymphoma) conditions. The value of age or LDH
assessing risk and prognosis has been well established over the years in
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different prognostic scales (international prognostic index, follicular lymphoma
international prognostic index) [131]. Immunohistochemistry alone will misclassify
an abundant group of patients; immunohistochemistry plus molecular profiling
and clinical variables as age or race will be a robust way of understanding a
patient’s tumor. Mechanistically, whether or not these laboratorial variables (LDH,
beta-2 microglobulin, albumin, etc.) are superficial surrogates of a much deeper
biology of the tumor and/or the host remains to be seen. That said, a feeling of
unfairness settles in when comparing the humble LDH to the power unlocked by
the prowess in generating data from the human genome project as it is
identifying candidate genes for genetic cancer predisposition, loss-of-function for
tumor suppressing genes versus gain-of-function oncogenes as possible targets.
Furthermore, this loss-of-function for tumor suppressing genes may occur
secondary to hypermethylating the promoter for that particular gene, abrogation
of one genetic copy (allele) or loss of heterozygosity, and abrogation of both
gene copies (parental alleles) or homozygous deletion. Molecular studies are
meant to compliment, not replace, the breadth of knowledge regarding prognostic
and diagnostic variables that we already have in hand.

The Vogelstein model - Sequential versus catastrophic aberrations:

The Vogelstein model speaks about a step-by-step malignant evolution
[132]. The Knudson’s “two-hit” theory speaks about an initial mutation followed by
a second mutation can develop neoplasia [133]. A similar pattern of a
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subsequent molecular cascade promoting proliferation has been suggested to
occur with retinoblastoma, helicobacter pylori, and other infectious agents as
Epstein Barr virus and human papilloma virus; although it has been difficult to
confirm. Multiple genetic and epigenetic aberrations following the Vogelstein
model in colorectal cancer have been tried to apply to other malignancies;
nevertheless these mutations do not necessarily follow a sequential pattern of
acquisition and accumulation of molecular abnormalities. The
adenoma/carcinoma stepwise approach (initiation, promotion, progression) of the
Vogelstein theory has been challenged as some aberrations are present at early
stages and no longer found in advanced disease, and the dynamic malignant
process of de-differentiation/re-differentiation does not seem to be a linear
process of rather irreversible molecular aberrations. Such bidirectional
differentiation dynamism is exemplified by beta-catenin as part of the Wnt
signaling pathway, which under normal conditions regulates embryonic
morphogenesis depending on a temporal coordination of events; but also when
hyperactive, perhaps due to molecular perturbations produced by Helycobacter
pylori, can stimulate proliferation and tumor invasion.

Solid tumors - Much to learn from their hematologic counterparts:

Neoplastic cells convey advantages over the soon-to-be outnumbered
normal cells resulting in a clonal evolution and expansion of the fittest. BRAF
mutations are common in some solid malignancies but rare in liquid neoplasms
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with the exception of Hairy cell leukemia. Trisomy 8 is common in some liquid
malignancies but rare in solid neoplasms with the exception of desmoid tumors.

Passed discrepancies, the anti-apoptotic family of the B cell
leukemia/lymphoma 2 or Bcl-2, with their members, Bcl-xL and Bcl-2, has been
identified in both liquid and solid tumors as head and neck malignancies. Beyond
AML, multiple molecular markers have appeared in recent times in other
hematological malignancies as myelodysplastic syndromes (TET2, DNMT3A,
ASXL1, EXH2, U2AF1, etc.), chronic lymphocytic leukemia (NOTCH1, XPO1,
MYD88, KLH6, etc.), acute lymphoblastic leukemia (ETV6, RUNX1,
rearrangements of the cytokine receptor gene CRLF2, alterations of the lymphoid
transcription factor gene IKZF1 or IKAROS, etc.), and multiple myeloma (FGFR3,
MMSET, MAFB, etc.). Hematological malignancies are ahead of their solid
counterparts in part due to the ease of genetic evaluation (e.g. peripheral blood
assessment). It remains to be seen whether most of these aberrations are
“driver” mutations creating oncogene-addiction, or mere “passenger” mutations
admiring the landscape while our patients cruise through the path of molecular
evolution. Complex as it seems, these multiple aberrations will soon stratify
patients in different small subsets of mutations and once found to be druggable
targets, extrapolations may be made across malignancies in clinical trials (i.e.
BRAF inhibition with vemurafenib in BRAF-mutated Hairy cell leukemia).
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From myeloma to melanoma and back - More than phonetics:

Most melanomas carry aberrations in MAPK which is a cascade of
activating phosphorylation including KRAS, BRAF (and/or a parallel path through
CRAF that requires additional steps for activation), MEK, and finally ERK. The
microphthalmia-associated transcription factor (MITF), critical in the process of
melanin production, has been found to be mutated in some instances as well.
Clinically, melanoma has been divided into cutaneous, uveal and acral/mucosal.
Molecularly, these clinical subgroups have their own characteristic aberrations as
BRAF/NRAS mutations, GNAQ/GNA11/BAP1 or BRCA1-associated protein 1,
and KIT, respectively. Up close and personalized, melanoma could be tackled by
targeted inhibition of BRAF, MEK, NRAS, and KIT. MEK inhibitors as trametinib
and MEK162 have shown responses in patients with melanomas harboring
BRAFV600 & NRAS mutations. BRAF inhibitors as vemurafenib and dabrafenib
(GSK2118436) displayed dramatic improvements in BRAF-mutated melanoma.
Imatinib may have activity in KIT-mutant melanoma although initial trials have
been disappointing. Interestingly, BRAF inhibition may cause worsening of preexistent RAS mutated conditions and newly diagnosed squamous cell carcinoma,
keratoacanthoma, second primary melanomas and worsening of RAS-mutant
chronic myelomonocytic leukemia have been described. Not surprisingly, the
pairing of BRAF plus MEK inhibitors in clinical trials appears to produce less
dermatologic toxicity perhaps due to further downstream blockade of possible
escape pathways. As angiogenesis seems to be hyperactive in melanoma,
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bevacizumab has been evaluated with carboplatin plus paclitaxel. Despite the
fact that bevacizumab targets the vascular endothelial growth factor or VEGF
some may argue that we do not really have a molecular target at this point that
would help us to select patients. Desperate to find a subgroup that will be setup
for therapeutic success, investigators looked back at the subset of patients with
elevated LDH only to find overall survival benefit after bevacizumab challenge
which proves our point that even the most extensive molecular evaluations might
not completely replace basic laboratorial data. Multiple myeloma has many things
to learn from melanoma as the search for oncogenic drivers, targeted therapy
and molecular stratification of patients. Melanoma has many things to learn from
multiple myeloma as the investigator’s drive to design combinatorial trials to
overcome resistance as quadruplets (i.e. VCRD or bortezomib,
cyclophosphamide, lenalidomide, dexamethasone) and then some (i.e. VDTPACE or bortezomib-dexamethasone-thalidomide, and cisplatin-doxorubicincyclophosphamide-etoposide). Myeloma trials do not only vehemently group
drugs together, but they also bring up new agents aggressively to the frontline in
newly diagnosed patients, instead of waiting for heavily pretreated individuals
that are less likely to respond, which has allowed them to obtain responses near
100% and word in the street is that a cure is near for this plasma cell dyscrasia.
Interestingly, a very small subset of patients (4%) with multiple myeloma will
carry BRAF mutations [126]. The value of targeting BRAF-mutant myeloma
patients with BRAF inhibitors is currently unknown. NRAS (24%) and KRAS
(27%) mutations have been found in myeloma as well. If we erase the arbitrary
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limits between malignant hematology and oncology, myeloma and melanoma are
not so far apart beyond linguistic connotations; and a successful therapeutic
formula may be extrapolated from one disease to another irrespective of its
chapter in medicine textbooks.

Lung cancer - Divide and conquer:

Multiple drugs have increased the armamentarium against NSCLC
including erlotinib for EGFR and crizotinib for anaplastic lymphoma kinase (ALK)
and ROS1 translocation. KRAS mutations are being challenged by selumetinib
which is an oral MEK inhibitor downstream from KRAS (non-impressive results
from farnesyl protein transferase inhibitors in NSCLC population so far), PIK3CA
mutations with ridaforolimus which is an mTOR inhibitor, BRAF mutations with
vemurafenib which is a BRAF inhibitor, RET translocations with vandetanib
(multi-tyrosine kinase drug), DDR2 mutation with dasatinib, HER2 expression
with afatinib which is an EGFR/HER2 tyrosine kinase inhibitor (non-impressive
results of trastuzumab in the HER2 amplified NSCLC population so far), and
MET expression with tivantinib which is a MET tyrosine kinase inhibitor.
Interestingly, crizotinib was originally developed as a MET inhibitor and it seems
to be active in patients with NSCLC that express MET. Needless to say, crizotinib
as an ALK inhibitor is also under evaluation in hematologic malignancies as
anaplastic lymphoma which gave birth to the name of such tyrosine kinase (ALK
or anaplastic lymphoma kinase).
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Prognostic versus predictive - The nail and the hammer:

Just as when you choose your specialist in medicine, you choose your
disease (i.e. an orthopedic surgeon recommending an arthroscopic procedure for
osteoarthritis). When you have a hammer, everything looks like a nail; thus it is
not surprising that oncologists have been treating patients blindly with cytotoxic
chemotherapy for the longest time. Following the above example,
immunohistochemistry revealing HER-2 overexpressed breast cancer, reminds
us of the abundant benefits brought upon patients after finding a nail (i.e. the
abnormal HER-2 pathway) and hammering it at frontline, relapse and even
during continuation despite progression (trastuzumab, lapatinib, T-DM1).
Interestingly, a tumor being identified as HER2-enriched subtype (high HER2
expression and low basal/luminal expression) does not automatically mean that it
is a clinically HER2 overexpressed breast cancer. On the other hand, some
HER2-enriched subtype tumors are clinically HER2-negative breast cancers and
the possible use of HER2 as a therapeutic target in such population is under
evaluation. At the end of the day, it makes sense that the evaluation of multiple
genes involved in the production of a protein (i.e. HER2 hormonal receptor) might
be a more thorough assessment than the evaluation of an abnormality by a
single immunochemistry stain (HER2 positivity 2+). HER2-overexpression has
been a well-known factor heralding poor prognosis (i.e. increased brain
metastasis, shorter survival, etc.), although it is until the development of HER2-
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targeted therapy that a negative factor became a positive predictive one.
Similarly, AML has new poor prognostic aberrations (i.e. FLT3) and perhaps it
will be under the development of novel drugs (i.e. novel FLT3 inhibitors as
quizartinib) that a negative factor will become a positive one. From a therapeutic
point of view, discovering targeted therapy directed against the ubiquitous p53
and KRAS mutations may become the “holy grail” for multiple tumors, including
gastrointestinal malignancies, nevertheless currently they remain in the dark.
With the arrival of more refined molecular diagnostic tests, a multitude of nails
have been brought to our working table; nevertheless at the end of the day
having endless nails are worthless gadgets without having a hammer to use
them. It will take time and heavy investment on research to pair druggable
aberrations to matched targeted therapies.

CML - A full circle:

CML is used across the board as the paradigm of personalized medicine
and physician-scientists are in a quest to find the next “imatinib-like” agent;
nevertheless its impressive results, imatinib is not magic and a percentage of
patients are resistant and ultimately progress. Molecular evaluation was critical to
understand why this occurred (i.e. T315I mutation) and the development of
second and third generation tyrosine kinase inhibitor to overcome such
resistance. Interestingly, the advent of the powerful pan-ABL1 kinase inhibitor
ponatinib [134] with response rates near 100% in patients with or without the
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current known resistant mutations makes unnecessary testing for these
aberrations.

A word of caution:

Targeted single-agent therapy is no panacea. Ovarian high grade serous
carcinomas also express high levels of estrogen receptors albeit response rates
to hormonal manipulation have been low (approximately 10%) [135]. Targeting ckit in GIST only showed a 38% response [136], and acute myeloid leukemia, no
clinical responses as single agent maneuver [137], do not yield the same
responses hence generalizations should be made cautiously. Furthermore,
sporadic medullary thyroid cancer may show responses to RET inhibitors even
without RET mutations. Technical limitations may include the fact that gene
profiles obtained from formalin-fixed samples might not be the same as
assessing banked frozen tissue. To further complicate the situation, different
particular platforms have different specific requirements (frozen unfixed sample
placed, within a brief lapse of time following surgery, in a particular container to
be sent to a particular molecular profiling company). Profiling different areas of a
same tumor, or different metastatic sites stemming from a single tumor, might
provide discordant results due to tumor heterogeneity. Timing (early versus late)
and location (local versus distant) might also factor in as these variables might be
a surrogate of the existence of a different disease that evolves over time; thus it
is critical to apply molecular profiling data to the exact setting that was initially
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studied. Beyond offering potential targets for treatment selection that can
augment the chances of observing responses; high-risk versus low-risk
discordance between molecular and clinical predictors will be expected in a
subgroup of patients and treatment decisions might be difficult until large
prospective matters settle this matter.

Personalized cancer drugs with their potent, albeit transient, responses
may never “cure” patients because cancer genomes are not the only culprit for
malignant development or poor prognosis. The molecular makeup of the host
and the tumor microenvironment probably play a role as well. A limited tumoronly molecular evaluation of genes could potentially misclassify a patient as low
risk of mortality (i.e. chronic lymphocytic leukemia), when such patient actually
carried high risk variables for heart disease or thromboembolic events, which
sadly would ultimately cause the patient’s demise in a swift fashion. The new
molecular technologies will be able to locate minuscule numbers of abnormal
genes despite being admixed among countless normal genes which will be used
to our advantage when it comes to screening; although a diagnostic conundrum
may arise after discovering a new mutation associated with particular genotypephenotype malignant presentations in an asymptomatic patient (prophylactic
surgical removal versus watch-and-worry with aggressive interval screening).
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Future directions - On the non-labeling of patients and combinatorial
clinical trials:

Light microscopy can only illuminate so far when it comes to poorly
differentiated malignancies. In the case of carcinomas of unknown primary, an
aberration-specific approach may guide our therapeutic decisions in lack of an
organ-specific approach. Certain gene expression profiles obtained from tumors
may guide towards the normal tissue of origin in a site-specific approach. As
such, a treatment paradigm has risen that knows no boundaries when it comes to
differentiating malignant hematology versus oncology (i.e. vemurafenib use in
BRAF-mutant Hairy cell leukemia) or site of origin (i.e. HER2 overexpressed
gastric cancer as “druggable” aberrations previously believed to be exclusive of
breast cancer). In the past, familial neoplasms shed light upon the presence of
inherited genetic germline mutations as trials studied the affected kindred. In the
future, each individual patient may be a trial of its own as molecular profiling
might reveal acquired somatic genetic mutations amenable to targeted therapy.
As a cautionary note, finding a target in a pathway is not a guarantee of
response. Heavily pretreated PIK3CA-mutated colon neoplasia that received
trials incorporating PI3K/AKT/mTOR inhibitors showed minimal activity [138].

Finding an aberrant pathway (i.e. PDGFRA) may unify both common and
rare tumors and standardize a therapy (i.e. imatinib mesylate for KIT-negative
GIST, Erdheim-Chester disease, desmoid tumors, and dermatofibrosarcoma
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protuberans). It has been a decade since the Human Genome Project;
nevertheless translating such massive collection of information to the clinic has
remained an elusive goal due to technical and economic issues. In this world of
instant gratification, molecular profiling and genome sequencing during routine
checkups will soon no longer be utopia (Illumina Inc., Life Technologies, Oxford
Nanopore Technologies, Noblegen Biosciences, etc.). As seen through deep
gene-sequencing, cancer is not only one disease; hence the true challenge will
be to match a tumor to a drug. Beyond wide genome profiling, high-throughput
technology will also evaluate proteins (proteomics), or cellular metabolism
(metabolomics) that can be exploited towards prognostic stratification and
therapeutic decision-making. At the end of the day, you do not want to treat your
patients with cancer based on the molecular analysis performed at diagnosis five
years ago; you want real-time high-throughput molecular data now.

Phase I clinical trial design looking for the maximum tolerated dose comes
from the original chemotherapy trials; perhaps trials looking for the minimum
effective dose are more applicable to the era of targeted agents. With limited
resources, the mathematical number of possible combinations of targeted agents
is not feasible to pursue unless we have a strong pre-clinical rationale in drug
development.
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Conclusion:

Protocol 2012-0153 is currently IRB approved and already enrolling patients to
determine MTD plus preliminary antitumor activity (tumor response) of the
combination of vemurafenib and everolimus. Suggested completion timeframe for
protocol 2012-0153 is within three years of accrual start date. Preliminary data
from initial ten patients enrolled show encouraging results.
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APPENDIX: DRUG INFORMATION

Everolimus:

Everolimus (Afinitor®), side effects: Angioedema, marrow suppression,
generalized/localized edema, azoospermia/oligospermia, infection, malignancy,
mucositis/stomatitis, nephrotoxicity, noninfectious pneumonitis (which might
require dosage modification or corticosteroid therapy) and wound healing
complication. Side effects occurring in more than 10% of cases as follows:
Cardiovascular: Peripheral edema (4% to 45%), hypertension (4% to 30%).
Central nervous system: Fatigue (7% to 45%), fever (19% to 32%), headache
(18% to 30%), seizure (SEGA: 29%), personality change (SEGA: 18%), insomnia
(9% to 17%), dizziness (7% to 14%). Dermatologic: Rash (18% to 59%), acneiform
dermatitis (SEGA: 25%; RCC: 3%), cellulitis (SEGA: 21%), nail disorders (5% to
22%), pruritus (14% to 21%), dry skin (13% to 18%), contact dermatitis (14%),
excoriation (14%), acne (11%). Endocrine & metabolic: Hypercholesterolemia
(17% to 77%), hyperglycemia (12% to 75%; Grades 3/4: <1% to 17%),
hypertriglyceridemia (≤73%), bicarbonate decreased (≤56%), hypophosphatemia
(13% to 40%), hypocalcemia (17% to 37%), hypoglycemia (≤32%), hypokalemia
(12% to 23%), hyperlipidemia (renal transplant: 21%), hyperkalemia (renal
transplant: 18%), dyslipidemia (renal transplant: 15%), hypomagnesemia (renal
transplant:

14%),

hyponatremia

(≤16%),

albumin

decreased

(≤13%).
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Gastrointestinal: Stomatitis (oncology uses: 44% to 86%; Grade 3: 4% to 7%;
Grade 4: <1%; renal transplant: 8%), diarrhea (19% to 50%; Grade 3: ≤5%; Grade
4: <1%), constipation (11% to 38%), abdominal pain (3% to 36%), nausea (26% to
32%: Grade 3: 1% to 2%), anorexia (1% to 30%), vomiting (15% to 29%; Grade 3:
1% to 2% ), weight loss (9% to 28%), taste alteration (10% to 19%), gastroenteritis
(1% to 18%), xerostomia (8% to 11%). Genitourinary: Urinary tract infection (renal
transplant: 16% to 22%; RCC 5%), dysuria (renal transplant: 11%). Hematologic:
Anemia (26% to 92%; Grades 3/4; 13% to 15%), leukopenia (oncology uses: 26%
to 54%; renal transplant 3%), and others. Neuromuscular & skeletal: Weakness
(19% to 33%), arthralgia (≤15%), back pain (11% to 15%), limb pain (10% to 14%).
Otic: Otitis (SEGA: 14% to 36%). Renal: Creatinine increased (11% to 50%),
hematuria (renal transplant: 12%). Respiratory: Upper respiratory infection (16%
to 82%), sinusitis (3% to 39%), cough (7% to 30%), dyspnea (20% to 24%; Grade
3: 2% to 6%; Grade 4: ≤1%), epistaxis (≤22%), pneumonitis (14% to 17%; Grade
3: 3% to 4%), nasal congestion (14%), rhinitis (14%), pharyngitis (4% to 11%).
Miscellaneous: Infection (RCC: All infections: 37%; Grade 3: 7%; Grade 4: 3%;
renal transplant: 62%).
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